Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CABA Stock Forecast 2026-2027
$3.06
Current Price
$294.57M
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CABA Price Targets
+880.4%
To High Target of $30.00
+357.5%
To Median Target of $14.00
-34.6%
To Low Target of $2.00
CABA Price Momentum
-3.5%
1 Week Change
+9.3%
1 Month Change
+68.1%
1 Year Change
+39.7%
Year-to-Date Change
-19.0%
From 52W High of $3.78
+210.3%
From 52W Low of $0.99
📊 TOP ANALYST CALLS
Did CABA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cabaletta is one of their latest high-conviction picks.
Latest CABA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, CABA has a bullish consensus with a median price target of $14.00 (ranging from $2.00 to $30.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.06, the median forecast implies a 357.5% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 880.4% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 34.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CABA Analyst Ratings
8
Buy
2
Hold
0
Sell
CABA Price Target Range
Low
$2.00
Average
$14.00
High
$30.00
Current: $3.06
Latest CABA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CABA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Maintains | $30.00 |
| Oct 10, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $16.00 |
| Sep 5, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $15.00 |
| Aug 14, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $10.00 |
| Aug 8, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $15.00 |
| Aug 8, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $2.00 |
| Jun 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| May 16, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $25.00 |
| May 16, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $13.00 |
| May 15, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $25.00 |
| Apr 1, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $3.00 |
| Apr 1, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $23.00 |
| Apr 1, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $22.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Apr 1, 2025 | UBS | Trung Huynh | Buy | Maintains | $7.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Dec 20, 2024 | Evercore ISI Group | Gavin Clark-Gartner | In-Line | Downgrade | $6.00 |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $6.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
Cabaletta Bio Inc. (CABA) Competitors
The following stocks are similar to Cabaletta based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cabaletta Bio Inc. (CABA) Financial Data
Cabaletta Bio Inc. has a market capitalization of $294.57M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -101.1%.
Valuation Metrics
Market Cap
$294.57M
Enterprise Value
$172.94M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+54.3%
Current Ratio
3.6x
Debt/Equity
18.5x
ROE
-101.1%
ROA
-51.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cabaletta Bio Inc. (CABA) Business Model
About Cabaletta Bio Inc.
What They Do
Develops engineered T cell therapies for autoimmune diseases.
Business Model
Cabaletta Bio operates as a clinical-stage biotechnology company focused on developing novel T cell therapies. The company generates potential revenue through its lead candidate, rese-cel, which is currently in Phase 1/2 clinical trials targeting various autoimmune diseases. By advancing its CABA platform and collaborating with prestigious institutions, Cabaletta Bio aims to deliver innovative therapies that could transform treatment approaches in the autoimmune disease sector.
Additional Information
Cabaletta Bio is headquartered in Philadelphia, Pennsylvania, and collaborates with renowned institutions such as the University of Pennsylvania and Children's Hospital of Philadelphia. The company is also developing additional therapies like DSG3-CAART and MuSK-CAART, expanding its focus on diverse autoimmune conditions across rheumatology, neurology, and dermatology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
148
CEO
Dr. Steven A. Nichtberger M.D.
Country
United States
IPO Year
2019
Website
www.cabalettabio.comCabaletta Bio Inc. (CABA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mar 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Cabaletta Bio (CABA) has been upgraded to Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may positively impact the stock price.
Why It Matters
Cabaletta Bio's upgrade to a Zacks Rank #2 signals increased confidence in its earnings potential, likely leading to a short-term stock price increase.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2026, at 11:10 a.m. ET in Boston.
Why It Matters
Cabaletta Bio's participation in a major healthcare conference signals potential visibility and interest in its innovative therapies, which could impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, at 9:30 a.m. ET in New York.
Why It Matters
Cabaletta Bio's participation in a prominent biotech summit highlights its visibility and potential investor interest, signaling advancements in curative therapies for autoimmune diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio, Inc. (CABA) is being assessed for its potential as a top stock pick for momentum investors.
Why It Matters
Cabaletta Bio's potential as a top stock pick for momentum investors suggests strong growth prospects, which could attract interest and drive stock price movements.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have exhibited performance metrics that can be compared to their sector's results for the year to date.
Why It Matters
Performance comparisons reveal trends, investor sentiment, and potential growth opportunities within sectors, influencing investment decisions for Cabaletta Bio, Inc. and Celcuity, Inc.
Source: Zacks Investment Research
Market Sentiment:
Positive
Cabaletta Bio: Do You Buy With The Insiders?
1 month ago
Quick Summary
Cabaletta Bio is progressing in its engineered cell therapy for autoimmune diseases. As of Q3 2025, it has $60.2M in cash and $99.7M in short-term investments, with recent insider purchases boosting confidence.
Why It Matters
Cabaletta Bio's progress in cell therapy and insider purchases signal confidence, while strong cash reserves enhance funding for development, potentially boosting investor sentiment and stock value.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CABA Stock
What is Cabaletta Bio Inc.'s (CABA) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Cabaletta Bio Inc. (CABA) has a median price target of $14.00. The highest price target is $30.00 and the lowest is $2.00.
Is CABA stock a good investment in 2026?
According to current analyst ratings, CABA has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CABA stock?
Wall Street analysts predict CABA stock could reach $14.00 in the next 12 months. This represents a 357.5% increase from the current price of $3.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cabaletta Bio Inc.'s business model?
Cabaletta Bio operates as a clinical-stage biotechnology company focused on developing novel T cell therapies. The company generates potential revenue through its lead candidate, rese-cel, which is currently in Phase 1/2 clinical trials targeting various autoimmune diseases. By advancing its CABA platform and collaborating with prestigious institutions, Cabaletta Bio aims to deliver innovative therapies that could transform treatment approaches in the autoimmune disease sector.
What is the highest forecasted price for CABA Cabaletta Bio Inc.?
The highest price target for CABA is $30.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 880.4% increase from the current price of $3.06.
What is the lowest forecasted price for CABA Cabaletta Bio Inc.?
The lowest price target for CABA is $2.00 from Derek Archila at Wells Fargo, which represents a -34.6% decrease from the current price of $3.06.
What is the overall CABA consensus from analysts for Cabaletta Bio Inc.?
The overall analyst consensus for CABA is bullish. Out of 15 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are CABA stock price projections?
Stock price projections, including those for Cabaletta Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 10:58 AM UTC